Detalles de la búsqueda
1.
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
Oncologist
; 28(9): 771-779, 2023 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37023721
2.
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
BMC Cancer
; 23(1): 908, 2023 Sep 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37752423
3.
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Br J Cancer
; 127(5): 957-967, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35665778
4.
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.
Br J Cancer
; 126(3): 449-455, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34811502
5.
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.
Oncologist
; 26(12): 1079-1084, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34355463
6.
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Breast Cancer Res
; 22(1): 33, 2020 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32252811
7.
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
Oncologist
; 25(9): 803-809, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32369650
8.
Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
Future Oncol
; 15(26): 3015-3024, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31424273
9.
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.
Future Oncol
; 13(19): 1677-1683, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28580793
10.
Are Cyclin-Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?
Oncologist
; 25(8): e1257-e1258, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32436279
11.
Oxidative, metabolic, and apoptotic responses of Schwann cells to high glucose levels.
J Biochem Mol Toxicol
; 29(6): 274-9, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25683646
12.
Time-course of protection by the selective A2A receptor antagonist SCH58261 after transient focal cerebral ischemia.
Neurol Sci
; 36(8): 1441-8, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25805704
13.
Multidisciplinary Approach to the Diagnosis of Occult Primary Neuroendocrine Neoplasm: A Clinical Challenge.
J Clin Med
; 12(17)2023 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37685605
14.
Comparative analysis of wild-type and chloroplast MCU-deficient plants reveals multiple consequences of chloroplast calcium handling under drought stress.
Front Plant Sci
; 14: 1228060, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37692417
15.
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer.
J Immunother Cancer
; 11(1)2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36593068
16.
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Eur J Cancer
; 187: 15-24, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37099945
17.
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors.
Clin Cancer Res
; 29(18): 3771-3778, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439810
18.
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
J Hematol Oncol
; 16(1): 119, 2023 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38098114
19.
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
Crit Rev Oncol Hematol
; 169: 103532, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34800655
20.
Metastatic pheochromocytomas and paragangliomas: where are we?
Tumori
; 108(6): 526-540, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35593402